Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has announced groundbreaking clinical trials for MB22001, a form of LSD, targeting PMS and PMDD in menstruating individuals. The trials are significant as they are the first in the world to allow take-home use of such a drug, with MindBio being the only company with regulatory approval for this. MB22001, which has shown mood-elevating and antidepressant effects in early trials, addresses the substantial unmet need for effective treatments in women’s health, particularly for the 25% of menstruating women affected by PMS symptoms.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
